Klin Onkol 2000; 13(Speciál2 2000): 37-38.
Summary: Preliminary information is presented on outcomes of in vitro MTT chemoresistance testing in 60 carcinomas of lung, colon and rectum and soft tissue sarcomas. Primary chemoresistance could be observed in lung carcinomas in 8% for cisplatin, 33% for topotecan, 40% for carboplatin, 50% for vinorelbine, 60% for vincristine, 82% for paclitaxel and in all cases for doxorubicine, mitomycin C and 5-fluorouracil. The most successful combinations were cisplatin plus topotecan and cisplatin with vinorelbine. The platinum analogues were the most efficient drugs in vitro also in colorectal carcinoma. The chemoresistance to 5-fluorouracil approaching to 80% corresponds to some 20% effectivity of this drug observed in clinical studies with standard 5-FU regimens. Five of twenty two soft tissue sarcomas showed chemoresistance to all tested drugs. In remaining 17 cases the lowest resistance was reported for actinomycin D, topotecan and cisplatin. 80% sarcomas were resistant to doxorubicine. Not only more experience in needed with this individualized approach to cancer chemotherapy, but also contribution of clinicians on interpretation of testing and correlation studies of tailored chemotherapy.
